Management of Recurrent Hepatitis C Infection after Liver Transplantation

Clinics in Liver Disease

Volumn 15, Issue 4, 2011, Pages 845-858

  Limaye, Alpna R ^a   Firpi, Roberto J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Hepatitis C; Liver transplant; Management; Recurrent

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; TACROLIMUS;

DONOR; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NONHUMAN; PREDICTOR VARIABLE; RECIPIENT; RECURRENT DISEASE; RETRANSPLANTATION; REVIEW; VIRUS LOAD;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; PROGNOSIS; RECURRENCE; REOPERATION; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 80054954984     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.08.003     Document Type: Review

References (91)

1. World Health Organization. Available at: Accessed February 28, 2011. http://www.who.org.
2. OPTN/SRTR 2009 Annual Report Chapter IV: liver transplantation in the United States, 1999-2008 Available at:, Accessed February 28, 2011. http://optn.transplant.hrsa.gov/ar2009/Chapter_IV_AR_CD.htm.
3. Firpi R.J., Clark V., Soldevila-Pico C., et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl 2009, 15(9):1063-1071.
4. Neumann U.P., Berg T., Bahra M., et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004, 41(5):830-836.
5. Sanchez-Fueyo A., Restrepo J.C., Quinto L., et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2001, 73(1):56-63.
6. Weisner R.H., Sorrell M., Villamil F., International Liver Transplantation Society Expert Panel Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003, 9(11):S1-S9.
7. Powers K.A., Ribeiro R.M., Patel K., et al. Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl 2006, 12(2):207-216.
8. Garcia-Retortillo M., Forns X., Feliu A., et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002, 35(3):680-687.
9. Haque M., Hashim A., Greanya E.D., et al. Spontaneous clearance of hepatitis C infection post-liver transplant: a rare but real phenomenon? a case report and review of the literature. Ann Hepatol 2010, 9(2):202-206.
10. Sreekumar R., Gonzalez-Koch A., Maor-Kendler Y., et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000, 32(5):1125-1130.
11. Rayhill S.C., Wu Y.M., Katz D.A., et al. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation 2007, 84(3):331-339.
12. Machicao V.I., Bonatti H., Krishna M., et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004, 77(1):84-92.
13. Perez-Daga J.A., Ramirez-Plaza C., Suarez M.A., et al. Impact of donor age on the results of liver transplantation in hepatitis C virus-positive recipients. Transplant Proc 2008, 40(9):2959-2961.
14. Condron S.L., Heneghan M.A., Patel K., et al. Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection. Transplantation 2005, 80(1):145-148.
15. Yagci G., Fernandez L.A., Knechtle S.J., et al. The impact of donor variables on the outcome of orthotopic liver transplantation for hepatitis C. Transplant Proc 2008, 40(1):219-223.
16. Tao R., Ruppert K., Cruz R.J., et al. Hepatitis C recurrence is not adversely affected by the use of donation after cardiac death liver allografts. Liver Transpl 2010, 16(11):1288-1295.
17. Olthoff K.M., Abecassis M.M., Emond J.C., A2ALL Study Group, et al. Outcomes for adult living donor liver transplantation: comparison of A2ALL and national experience. Liver Transpl 2011, 17(7):789-797.
18. Kuo A., Terrault N.A. Is recurrent hepatitis C worse with living donors?. Curr Opin Organ Transplant 2009, 14(3):240-244.
19. Russo M.W., Galanko J., Beavers K., et al. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl 2004, 10(3):340-346.
20. Terrault N.A., Shiffman M.L., Lok A.S., A2ALL Study Group, et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007, 13(1):122-129.
21. Gallegos-Orozco J.F., Yosephy A., Noble B., et al. Natural history of post-liver transplantation hepatitis C: a review of factors that may influence its course. Liver Transpl 2009, 15(12):1872-1881.
22. Briceno J., Ciria R., Pleguezuelo M., et al. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl 2009, 15(1):37-48.
23. Burra P., Loreno M., Russo F.P., et al. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl 2009, 15(6):619-628.
24. Reese P.P., Sonawane S.B., Thomasson A., et al. Donor age and cold ischemia interact to produce inferior 90-day liver allograft survival. Transplantation 2008, 85(12):1737-1744.
25. Cassuto J.R., Patel S.A., Tsoulfas G., et al. The cumulative effects of cold ischemic time and older donor age on liver graft survival. J Surg Res 2008, 148(1):38-44.
26. Michaels A., Dhanasekaran R., Alkhasawneh A., et al. The impact of preservation injury on accelerated hepatitis C recurrence after liver transplantation. Hepatology 2010, 52(Suppl 4). [abstract: 2]. In: AASLD Abstracts, 320A.
27. Charlton M., Ruppert K., Belle S.H., et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 2004, 10(9):1120-1130.
28. Belli L.S., Burroughs A.K., Burra P., et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007, 13(5):733-740.
29. Lai JC, Vema EC, Brown RS. Hepatitis C virus (HCV) infected females are at higher risk of graft loss after liver transplantation (LT): a multicenter cohort study. Abstract 6, presented November 1, 2009 at the liver meeting 2009: American Association for the Study of Liver Diseases 60th Annual Meeting. Boston (MA).
30. Testilano M., Fernandez J.R., Suarez M.J., et al. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center. Transplant Proc 2009, 41(3):1041-1043.
31. Duclos-Vallee J.C., Feray C., Sebagh M., THEVIC Study Group, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008, 47(2):407-417.
32. Burak K.W., Kremers W.K., Batts K.P., et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002, 8(4):362-369.
33. Charlton M.R., Thompson A., Veldt B.J., et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011, 53(1):317-324.
34. Charlton M., Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999, 5(4 Suppl 1):S107-S114.
35. Charlton M., Seaberg E., Wiesner R., et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998, 28(3):823-830.
36. Nelson D.R., Soldevila-Pico C., Reed A., et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001, 7(12):1064-1070.
37. Sgourakis G., Radtke A., Fouzas I., et al. Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int 2009, 22(9):892-905.
38. McAlister V.C., Haddad E., Renouf E., et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006, 6(7):1578-1585.
39. Berenguer M., Royuela A., Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcomes of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007, 13(1):21-29.
40. Levy G., Grazi G.L., Sanjuan F., et al. 12-month follow-up analysis of a multi-center, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl 2006, 12(10):1464-1472.
41. Manousou P., Samonakis D., Cholongitas E., et al. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl 2009, 15(12):1783-1791.
42. Berenguer M., Aguilera V., San Juan F., et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 2010, 90(11):1204-1209.
43. Cescon M., Grazi G.L., Cucchetti A., et al. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl 2009, 15(7):782-789.
44. Selzner N., Renner E.L., Selzner M., et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 2009, 88(10):1214-1221.
45. Firpi R.J., Soldevila-Pico C., Morelli G.G., et al. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig Dis Sci 2010, 55(1):196-203.
46. Cholongitas E., Tsochatzis E., Goulis J., et al. Noninvasive tests for evaluation of fibrosis in HCV recurrence after liver transplantation: a systematic review. Transpl Int 2010, 23(9):861-870.
47. Carrion J.A., Fernandez-Varo G., Bruguera M., et al. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology 2010, 138(1):147-158.
48. Berres M.L., Trautwein C., Schmeding M., et al. Serum chemokine CXC ligand 10 (CXCL 10) predicts fibrosis progression after liver transplantation for hepatitis C infection. Hepatology 2011, 53(2):596-603.
49. Bruno S., Stroffolini T., Colombo M., et al. Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007, 45(3):579-587.
50. Pradat P., Tillmann H.L., Sauleda S., HENCORE Group, et al. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat 2007, 14(8):556-563.
51. Nudo C.G., Cortes R.A., Weppler D., et al. Effect of pretransplant hepatitis C virus RNA status on posttransplant outcome. Transplant Proc 2008, 40(5):1449-1455.
52. Shiffman M.L., Di Bisceglie A.M., Lindsay K.L., et al. Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Peginterferon alfa-2a and ribavirin in patient with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004, 126(4):1015-1023.
53. Iacobellis A., Ippolito A., Andriulli A. Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. World J Gastroenterol 2008, 14(42):6467-6472.
54. Crippin J.S., McCashland T., Terrault N., et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002, 8(4):350-355.
55. Singh N., Gayowski T., Wannstedt C.F., et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation 1998, 65(1):82-86.
56. Sheiner P.A., Boros P., Klion F.M., et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998 Sep, 28(3):831-838.
57. Shergill A.K., Khalili M., Straley S., et al. Applicability, tolerability, and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005, 5(1):118-124.
58. Chalasani N., Manzarbeitia C., Ferenci P., Pegasys Transplant Study Group, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005, 41(2):289-298.
59. Sugawara Y., Makuuchi M., Matsui Y., et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004, 78(9):1308-1311.
60. Zimmermann T., Bocher W.O., Biesterfeld S., et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2-a plus ribavirin in the early phase of HCV reinfection. Transpl Int 2007, 20(7):583-590.
61. Castells L., Vargas V., Allende H., et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005, 43(1):53-59.
62. Xirouchakis E., Triantos C., Manousou P., et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled trials. J Viral Hepat 2008, 15(10):699-709.
63. Abdelmalek M.F., Firpi R.J., Soldevila-Pico C., et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004, 10(2):199-207.
64. Gane E.J., Lo S.K., Riordan S.M., et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998, 27(5):1403-1407.
65. Feray C., Samuel D., Gigou M., et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995, 22(4 Pt 1):1084-1089.
66. Ross A.S., Bhan A.K., Pascual M., et al. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004, 18(2):166-173.
67. Saab S., Kalmaz D., Gajjar N.A., et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004, 10(7):859-867.
68. Toniutto P., Fabris C., Fumo E., et al. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis c: comparison of tolerability and efficacy. J Gastroenterol Hepatol 2005, 20(4):577-582.
69. Stravitz R.T., Shiffman M.L., Sanyal A.J., et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004, 10(7):850-858.
70. Berenguer M., Palau A., Fernandez A., et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006, 12(7):1067-1076.
71. Mukherjee S., Lyden E., McCashland T.M., et al. Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients. J Gastroenterol Hepatol 2005, 20(2):198-203.
72. Bahra M., Neumann U.P., Jacob D., et al. Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy). Transplantation 2007, 83(3):351-353.
73. Sharma P., Marrero J.A., Fontana R.J., et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007, 13(8):1100-1108.
74. Dumortier J., Scoazec J.Y., Chevallier P., et al. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004, 40(4):669-674.
75. Oton E., Barcena R., Moreno-Planas J.M., et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006, 6(10):2348-2355.
76. Fernandez I., Meneu J.C., Colina F., et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006, 12(12):1805-1812.
77. Neumann U., Puhl G., Bahra M., et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006, 82(1):43-47.
78. Mukherjee S., Lyden E. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open label series. Hepatogastroenterology 2006, 53(70):561-565.
79. Mukherjee S., Lyden E. Impact of pegylated interferon alpha-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series. Liver Int 2006, 26(5):529-535.
80. Carrion J.A., Navasa M., Garcia-Retortillo M., et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007, 132(5):1746-1756.
81. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008, 49(2):274-287.
82. Bizollon T., Pradat P., Mabrut J.Y., et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005, 5(8):1909-1913.
83. Firpi R.J., Abdelmalek M.F., Soldevila-Pico C., et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002, 8(11):1000-1006.
84. Picciotto F.P., Tritto G., Lanza A.G., et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007, 46(3):459-465.
85. Kornberg A., Kupper B., Tannapfel A., et al. Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C. Transplantation 2008, 86(3):469-473.
86. Bizollon T., Pradat P., Mabrut J.Y., et al. Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation. Am J Transplant 2007, 7(2):448-453.
87. Kornberg A., Kupper B., Tannapfel A., et al. Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: pilot study. J Gastroenterol Hepatol 2007, 22(12):2135-2142.
88. Walter T., Scoazec J.Y., Guillaud O., et al. Long-term antiviral therapy for recurrent hepatitis C after liver transplantation in nonresponders: biochemical, virological, and histological impact. Liver Transpl 2009, 15(1):54-63.
89. Pawlotsky J.M. The results of phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus. Gastroenterology 2011, 140(3):746-754.
90. Carrion J.A., Navasa M., Forns X. Retransplantation in patients with hepatitis C recurrence after liver transplantation. J Hepatol 2010, 53(5):962-970.
91. Burton J.R., Sonnenberg A., Rosen H.R. Retransplantation for recurrent hepatitis C in the MELD era: maximizing utility. Liver Transpl 2004, 10(10 Suppl 2):S59-S64.